Analyst Report: MOH
1. EXECUTIVE SUMMARY
Molina Healthcare (MOH) surged by 6.82% to close at $135.35 on Friday, February 13, 2026 (the last active trading session before the Presidents' Day market holiday on February 16). This sharp reversal comes on the heels of a massive ~30% sell-off earlier in the month triggered by disappointed earnings guidance. The primary driver for this recovery is the release of 13-F filings and public commentary from famed "Big Short" investor Michael Burry (Scion Asset Management). Burry’s regulatory filings and vocal support have signaled to the market that the recent crash represents a "generational buy" opportunity, effectively putting a floor under the stock price and triggering a squeeze on short sellers who had piled in following the weak Q4 report.
2. THE CATALYST (CRITICAL)
- Event: 13-F Filing Release & "Super-Investor" Confidence Vote
- Date: The surge occurred during the trading session on Friday, February 13, 2026, in anticipation of the February 14 (Saturday) 13-F filing deadline.
- Details:
- Scion Asset Management (Michael Burry) confirmed in its 13-F filing (for the quarter ended Dec 31, 2025) that Molina Healthcare remains a top portfolio holding (approximately 35% of the portfolio).
- This filing follows Burry’s public comments (via X/Twitter) specifically addressing the stock's crash on February 6, where he stated he was "happy" to see the price dive because he understands the fundamental value, likening the opportunity to Warren Buffett’s historic bet on Geico.
- The market interpreted the 13-F confirmation—showing he did not panic-sell during the quarter—as a massive vote of confidence.
- Secondary Catalyst: Technical oversold conditions (RSI < 30) following the ~30% drop on February 5-6 created a prime setup for a relief rally once the "smart money" support was confirmed.
3. COMPANY PROFILE
- Official Name: Molina Healthcare, Inc.
- Ticker: MOH (NYSE)
- Core Business: Molina Healthcare provides managed healthcare services exclusively to low-income families and individuals under government-sponsored programs, including Medicaid, Medicare, and state insurance marketplaces (Obamacare).
- Sector: Healthcare / Managed Care
- Market Cap: ~$7.0 Billion (approximate, post-crash valuation)
- Key Competitors: Centene Corporation (CNC), Elevance Health (ELV), UnitedHealth Group (UNH).
- Performance Context:
- 52-Week Range: $121.06 - $359.97
- YTD Performance: Down ~45-50% (heavily impacted by the Feb 5 crash).
4. DEEP DIVE ANALYSIS
The "Value" vs. "Value Trap" Battleground
- The Bear Case (The Crash): On February 5, 2026, MOH crashed ~33% after reporting a disastrous Q4 2025 loss ($2.75/share adjusted) and slashing 2026 guidance to $5.00 EPS (vs. Wall Street expectations of ~$13.71). Management cited "unprecedented" medical cost trends and retroactive Medicaid clawbacks. The bear thesis is that Molina has lost control of its medical cost ratio (MCR) and that 2026 is not just a "trough" but the new normal of lower profitability.
- The Bull Case (The Surge): The "Burry Thesis" argues that the market reaction is an emotional capitulation. Bulls believe the 2026 guidance of $5.00 is an intentionally conservative "kitchen sink" forecast to reset expectations.
- Valuation: At ~$135, the stock trades at ~27x "trough" earnings but only ~9-10x normalized earnings (assuming a recovery to $14+ EPS in 2027/2028).
- Comparables: The situation mirrors past managed care cycles where regulatory headwinds caused temporary margin compression followed by multi-year recoveries.
- Institutional Action: Beyond Burry, 13-F data shows other value-oriented funds (e.g., Inspire Global Hope ETF, Evergreen Capital) accumulating shares, suggesting a rotation from "growth" investors to "deep value" investors is underway.
5. TECHNICAL SNAPSHOT
- Current Price: ~$135.35
- Key Support: $121.06 (The 52-week low hit on Feb 12/13). A break below this level would invalidate the reversal thesis.
- Key Resistance: $155 - $165 (The "Gap Fill" zone). The stock gapped down from ~$170 to ~$127 on earnings. The first major test for the bulls will be filling this gap.
- Volume: Volume on the surge was heavy, indicating strong institutional accumulation rather than just retail speculation.
- Indicators: RSI has bounced from extreme oversold territory (<20) to neutral-low levels, suggesting room for further upside before becoming overbought again.
6. RISK FACTORS
- Medicaid Redeterminations: Continued state-level scrutiny could lead to further membership losses or rate pressure.
- Medical Cost Ratio (MCR): If medical costs (utilization) do not stabilize in Q1/Q2 2026, the "trough year" guidance of $5.00 EPS could be revised even lower.
- Execution Risk: Management has promised a strategic exit from the unprofitable Medicare Advantage Part D business by 2027. Delays or higher-than-expected exit costs would hurt the stock.
- Volatility: As a "battleground stock" with high short interest and famous investors involved, expect wide daily price swings.
7. ACTIONABLE OUTLOOK
- Short-Term (1-2 Weeks): Bullish. Expect continued momentum as the "Burry Buy" news circulates and late short-sellers cover. The stock likely targets the $145-$150 level. Watch for a retest of the $128-$130 level to hold as a higher low.
- Medium-Term (1-3 Months): Neutral/Volatile. The stock will likely trade sideways in a range ($130 - $160) as the market waits for Q1 2026 earnings to verify if costs have stabilized.
- Long-Term Thesis: Contrarian Buy. If the 2026 "trough" thesis holds and earnings recover to historical norms ($12-$15 EPS) by 2027, the stock is fundamentally undervalued by 50-70%. This is a high-risk, high-reward turnaround play suitable for patient capital.